Mycofit (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycofit, is an antimetabolite immunosuppressant presented as an oral dosage form for oral use. It is used to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis and vasculitis.

GNH USA supplies Mycofit as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycofit is an antimetabolite immunosuppressant that acts on lymphocyte proliferation in several disease contexts. - Organ transplant rejection: helps prevent graft rejection by suppressing T‑cell activity. - Lupus nephritis: reduces renal inflammation by limiting immune complex formation. - Vasculitis: controls vessel inflammation through inhibition of B‑cell proliferation.

Mycofit may cause a range of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Infections: increased susceptibility to bacterial, viral, or fungal infections.

Serious or Rare Side Effects: - Hematologic abnormalities: anemia, leukopenia, or thrombocytopenia. - Hepatic injury: elevated transaminases or hepatitis. - Malignancy risk: rare reports of lymphoproliferative disorders.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess renal function: adjust therapy if creatinine clearance declines. - Avoid live vaccines: immunosuppression can lead to uncontrolled infection. - Contraindicated in pregnancy: category X, risk of fetal harm. - Use caution in hepatic impairment: monitor liver enzymes. - Store below 25°C: keep in original container, protect from moisture and direct sunlight.

Mycofit can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase mycophenolic acid exposure. - Live attenuated vaccines: heightened risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Warfarin: potential alteration of anticoagulant effect. - ACE inhibitors or ARBs: may exacerbate renal dysfunction. - Non‑live vaccines: monitor immune response efficacy.